Fredun Pharmaceuticals Limited (BOM:539730)
India · Delayed Price · Currency is INR | Market Cap | 24.04B +390.2% |
| Revenue (ttm) | 7.44B +49.7% |
| Net Income | 389.87M +74.2% |
| EPS | 23.48 +38.8% |
| Shares Out | 16.54M |
| PE Ratio | 61.90 |
| Forward PE | n/a |
| Dividend | 0.23 (0.02%) |
| Ex-Dividend Date | Jun 23, 2026 |
| Volume | 39,176 |
| Open | 1,599.95 |
| Previous Close | 1,547.75 |
| Day's Range | 1,408.90 - 1,600.00 |
| 52-Week Range | 343.33 - 1,600.00 |
| Beta | 0.69 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Fredun Pharmaceuticals
Fredun Pharmaceuticals Limited manufactures and sells pharmaceutical formulations, dietary/herbal supplements, nutraceuticals, animal healthcare products, cosmeceuticals, mobility and rehabilitation products, and other healthcare products in India, Africa, Southeast Asia, Commonwealth of Independent States countries, MENA region, and Latin America. The company offers allopathic formulations, including analgesics/NSAID, antacid/antiulcer, anthelmintic, antibacterial, anti-diabetic, anti-inflammatory, anti-malarial, anti-obesity, antacid, anthelm... [Read more]
Financial Performance
In fiscal year 2026, Fredun Pharmaceuticals's revenue was 6.35 billion, an increase of 40.03% compared to the previous year's 4.54 billion. Earnings were 326.21 million, an increase of 65.26%.
Financial StatementsNews
Fredun Pharmaceuticals Transcript: Q1 26/27
Q1 FY 2027 saw revenue surge 90% YoY to INR 228.25 crores, with net profit up 95% and margins improving. Growth is driven by new age brands, Pet Care, and Gx, with 30%-50% annual growth expected in key segments. Major CapEx and product launches are planned.
Fredun Pharmaceuticals Quarterly report: Q1 2027
Fredun Pharmaceuticals has published its Q1 2027 quarterly earnings report on August 13, 2026.
Fredun Pharmaceuticals Transcript: Q4 25/26
Q4 and FY 2026 saw robust revenue and profit growth, driven by strong performance in new age businesses like pet care and mobility, with margins expanding due to higher-value products and economies of scale. The company targets 25%-30% top-line growth for FY 2027 and expects PAT margins to reach 10%-12% in the coming years.
Fredun Pharmaceuticals Quarterly report: Q4 2026
Fredun Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 25, 2026.
Fredun Pharmaceuticals Annual report: Q4 2026
Fredun Pharmaceuticals has published its Q4 2026 annual report on May 25, 2026.
Fredun Pharmaceuticals Transcript: Q3 25/26
Q3 and nine-month results showed strong revenue and profit growth, with significant margin expansion and robust performance from both legacy and New Age businesses. Management expects continued growth, with New Age segments set to comprise over half of revenue by 2029-30.
Fredun Pharmaceuticals Quarterly report: Q3 2026
Fredun Pharmaceuticals has published its Q3 2026 quarterly earnings report on February 9, 2026.
Fredun Pharmaceuticals Transcript: Q2 25/26
Strong Q2 and H1 FY26 results with double-digit revenue and profit growth, driven by expansion in pet care, nutraceuticals, and mobility. Strategic acquisitions and manufacturing expansion support long-term growth, with positive cash flow and robust guidance for the coming years.
Fredun Pharmaceuticals Quarterly report: Q2 2026
Fredun Pharmaceuticals has published its Q2 2026 quarterly earnings report on November 11, 2025.
Fredun Pharmaceuticals stock jumps 3% after company set to launch advanced functional foods plant
Fredun Pharmaceuticals Limited saw a 3% jump in its stock price following the announcement of its new cutting-edge functional foods manufacturing facility. Located in Palghar, Maharashtra, this state-...